Topics
Articles about Anti-Aging Protocols
Is Rapamycin Being Overhyped? A Critical Analysis
Is rapamycin overhyped in the longevity community, or is it a scientific breakthrough that can finally slow human aging? While some claim it is the most promising anti-aging drug today, critics argue that the rapamycin longevity hype has outpaced the actual rapamycin anti-aging evidence in humans [1] [2]. Preclinical data shows rapamycin is the most…
Combining Rapamycin with Other Longevity Interventions: Metformin, NAD+, and More
Researchers now pursue human longevity through synergistic protocols instead of single-drug solutions. These combinations target the complex network of aging hallmarks simultaneously. Rapamycin remains the most effective drug for extending mammalian lifespans. However, real-world users often "stack" it with other interventions. People combine it with metformin, NAD+ precursors, and lifestyle changes. These additions enhance both…
The Bryan Johnson Case: What Went Wrong and What We Can Learn
Bryan Johnson, the tech entrepreneur spending $2 million a year to reverse his biological age, recently shocked the longevity community by announcing a Bryan Johnson Rapamycin reset. For a man who built his entire life around the Blueprint protocol, stopping a foundational longevity drug highlights the volatile nature of extreme biohacking. This decision followed a…
Rapamycin Bioavailability: Why Formulation Is the Hidden Variable in Longevity
The pursuit of longevity often leads researchers and self-experimenters to rapamycin, yet many fail to realize that sirolimus bioavailability is not a fixed number—it is a moving target dictated by chemical engineering. While the active molecule remains the same, the vehicle delivering it determines whether you achieve life-extending mTOR inhibition or simply expensive, unabsorbed waste.…



